Figure 4. Distinct TME characteristics and mutation of OS patients according to the risk score. (A) Abundance of 23 infiltrating immune cell types. (B) Correlations between risk score and both immune and stromal scores. (C) Correlations between risk score and immune checkpoints. (D) Predicts the responsiveness of OS to chemotherapy.